I would love to have a number for you right here. I don't have that number. I think that could definitely be something for a further study, to find out what that number should be.
To go back to your earlier point about the concern about all of this funding going in and then the results of that funding not coming out for public benefit, I think what we're proposing is exactly where this mechanism would be important, because I think that when CIHR is deciding to fund a university or some research, if they have this global access licence included in that funding.... Actually, the NIH in the U.S. has been playing with this, and it has some of these clauses included in some of the funding that it gives.
If you do that, it ensures that the university has to make the product of that research available. They can still license it to a pharmaceutical company. There's no problem. It just won't be an exclusive licence, so if that research leads to a medicine that could have benefits for people that the company is not able to provide those medicines to, then the university has the ability to license that out to another company or institution.